Michel Sadelain

Scientific Co-Founder at Juno Therapeutics, Inc.

Michel Sadelain

Michel Sadelain

Scientific Co-Founder at Juno Therapeutics, Inc.

Biography

Dr. Sadelain is the incumbent of the Stephen and Barbara Friedman chair and the founding director of the Center for Cell Engineering at MSKCC. He previously served on the board of directors of the American Society of Gene Therapy (2004-2007) and continues to serve on the editorial boards of Molecular Therapy, Human Gene Therapy and Gene Therapy.

T cell engineering is a promising approach to establish potent and durable immunity against cancer. The genetic modification of T lymphocytes is emerging as a powerful approach to investigate T cell function in vivo and, potentially, to bolster cancer immunotherapy. Dr. Sadelain’s research focuses on novel approaches to enhance T cell costimulation and function. His clinical program focuses on B cell malignancies, including on-going studies with CD19-targeted T cells in chronic lymphocytic leukemia and upcoming studies in acute leukemia and lymphoma, as well as solid tumors, including upcoming studies in metastatic prostate cancer.

Overview
Career Highlights

Juno Therapeutics, Inc.

RelSci Relationships

4765

Number of Boards

5

Contact Data
Trying to get in touch with Michel Sadelain? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Michel Sadelain likely has professional access to. A relationship does not necessarily indicate a personal connection.

Scientific Co-Founder at Juno Therapeutics, Inc.

Relationship likelihood: Strong

Chief, Thoracic Oncology Service, Co-Director, Druckenmiller Center for Lung Cancer Research & Sylvia Hassenfeld Chair in Lung Cancer Research at Memorial Sloan-Kettering Cancer Center

Relationship likelihood: Strong

President & Chief Executive Officer at Memorial Sloan-Kettering Cancer Center

Relationship likelihood: Strong

Endowed Chair in Molecular Oncogenesis at St. Jude Children's Research Hospital, Inc.

Relationship likelihood: Strong

Scientific Founder at Tmunity Therapeutics, Inc.

Relationship likelihood: Strong

Chief Operating Officer at Memorial Sloan-Kettering Cancer Center

Relationship likelihood: Strong

Anne Burnett Windfohr Chair of Clinical Oncology at Memorial Sloan-Kettering Cancer Center

Relationship likelihood: Strong

Benno C. Schmidt Chair in Clinical Oncology at Memorial Sloan-Kettering Cancer Center

Relationship likelihood: Strong

Laurence Joseph Dineen Chair in Leukemia Research at Memorial Sloan-Kettering Cancer Center

Relationship likelihood: Strong

Co-Founder at Blueprint Medicines Corp.

Relationship likelihood: Strong

Paths to Michel Sadelain
Potential Connections via
Relationship Science
You
Michel Sadelain
Scientific Co-Founder at Juno Therapeutics, Inc.
Career History
Scientific Co-Founder
Current

Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans E. Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, and Robert T. Nelsen on August 5, 2013 and is headquartered in Seattle, WA.

Director, Center for Cell Engineering, Stephen & Barbara Friedman Chair
Current

Memorial Sloan-Kettering Cancer Center — the world's oldest and largest private cancer center — has devoted more than 125 years to exceptional patient care, innovative research, and outstanding educational programs. Today, we are one of 41 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment. The close collaboration between our physicians and scientists is one of our unique strengths, enabling us to provide patients with the best care available as we work to discover more-effective strategies to prevent, control, and ultimately cure cancer in the future. Our education programs train future physicians and scientists, and the knowledge and experience they gain at Memorial Sloan-Kettering has an impact on cancer treatment and biomedical research around the world.

Associate Professor of Immunology in Medicine Associate Professor of Immunology in Pediatrics
Current

Founded in 1898, and affiliated with what is now NewYork-Presbyterian Hospital since 1927, Weill Cornell Medical College is among the top-ranked clinical and medical research centers in the country. In addition to offering degrees in medicine, Weill Cornell also has PhD programs in biomedical research and education at the Weill Cornell Graduate School of Medical Sciences, and with neighboring Sloan-Kettering Institute and The Rockefeller University, has established a joint MD-PhD program for students to intensify their pursuit of Weill Cornell's triple mission of education, research, and patient care. Weill Cornell Medical College is divided into 24 basic science and patient care departments that focus on the sciences underlying clinical medicine and/or encompass the study, treatment, and prevention of human diseases. In addition to its affiliation with NewYork-Presbyterian Hospital, Weill Cornell Medical College and the Weill Cornell Graduate School of Medical Sciences maintain major affiliations with Memorial Sloan-Kettering Cancer Center, The Rockefeller University, the Hospital for Special Surgery, as well as with the metropolitan-area institutions that constitute NewYork-Presbyterian Healthcare Network. Weill Cornell Medical College and the Weill Cornell Graduate School of Medical Sciences are accredited by the Liaison Committee for Medical Education of the American Medical Association and the Association of American Medical Colleges.

Boards & Committees
Member, Board of Directors
2004 - 2007
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Michel Sadelain. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Michel Sadelain's profile does not indicate a business or promotional relationship of any kind between RelSci and Michel Sadelain.